BioSpace News Archive

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of teclistamab for the treatment of patients with relapsed or refractory (R/R) multiple myeloma.

Hygiene and health company Essity has acquired the company Hydrofera.

ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced that Company management will present at the J.P. Morgan 40th Annual Healthcare Conference.

Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announces that they will present at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022, and at Biotech Showcase taking place January 10-12, 2022.

Altamira Therapeutics Ltd. today provided a business update on Bentrio™, its nasal spray for protection against airborne viruses and allergens.

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), announced today that its investment company Oravax Medical Inc. (“Oravax”), partially owned with its majority partner Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (“Oramed”), has signed a Cooperation and Purchase Agreement with Vietnam-based Tan Thanh Holdings Investment Joint Stock Company.

Aditxt, Inc. today announced it had signed an amendment to its February 3, 2020, Exclusive License Agreement with Stanford University, extending Aditxt’s exclusive right to license the technology deployed in AditxtScore™ and securing worldwide exclusivity in all fields of use of the licensed technology (the “Technology”).

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) announced today that the company is scheduled to present at the 40th Annual J. P. Morgan Healthcare Conference on January 13, 2022, at 9:45a.m. Eastern.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to report that Independent Review Board (“IRB”) approval has been received ahead of schedule for its upcoming DehydraTECH-CBD human hypertension study HYPER-H21-4.

Gardiner Healthcare Acquisitions Corp. (NASDAQ: GDNRU, the “Company”) announced today that an additional 1,125,000 units were issued pursuant to the underwriters’ exercise in full of its over-allotment option in connection with the Company’s initial public offering.